Assignee
NKARTA INC
US·6 granted patents·16 pending applications·32 citations·filing 2019–2025
Top patents by PatentIndex Score
22 records- 0194US11253547B2CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2020·Granted Feb 22, 2022·11 cites·19 claims
- 0294US11154575B2Cancer immunotherapy using CD19-directed chimeric antigen receptorsNKARTA INC·Filed 2020·Granted Oct 26, 2021·10 cites·25 claims
- 0394US11141436B2Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2020·Granted Oct 12, 2021·8 cites·16 claims
- 0489US12398187B2CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2022·Granted Aug 26, 2025·1 cites·24 claims
- 0588US12012458B2Genetically modified natural killer cells for CD70-directed cancer immunotherapyNKARTA INC·Filed 2021·Granted Jun 18, 2024·2 cites·26 claims
- 0675US2025296970A1Cd19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2025·Application pending·0 cites
- 0773US2026069530A1Methods of treating primary liver tumors with natural killer cells expressing a cytotoxic receptor complexNKARTA INC·Filed 2025·Application pending·0 cites
- 0871US2024360234A1Genetically modified natural killer cells for cd70-directed cancer immunotherapyNKARTA INC·Filed 2024·Application pending·0 cites
- 0963US2024358758A1Methods for treatment of autoimmune diseasesNKARTA INC·Filed 2024·Application pending·0 cites
- 1061US2025339528A1Selection of optimal cell donors and methods and compositions for enhanced expansion and cytotoxicity of donor cellsNKARTA INC·Filed 2022·Application pending·0 cites
- 1160US2026053925A1Dosing regimens for cd19-directed cancer immunotherapyNKARTA INC·Filed 2023·Application pending·0 cites
- 1259US2023390392A1Multiplex gene edited cells for cd70-directed cancer immunotherapyNKARTA INC·Filed 2023·Application pending·0 cites
- 1357US2025319185A1Bcma-directed cellular immunotherapy compositions and methodsNKARTA INC·Filed 2022·Application pending·0 cites
- 1457US2026000761A1Engineered immune cells with enhanced potency and uses of same in immunotherapyNKARTA INC·Filed 2023·Application pending·0 cites
- 1557US2021338727A1Natural killer cell compositions and immunotherapy methods for treating tumorsNKARTA INC·Filed 2019·Application pending·0 cites
- 1654US2025073266A1Dosing regimens for cancer immunotherapyNKARTA INC·Filed 2022·Application pending·0 cites
- 1754US2022411754A1Methods and compositions for enhanced expansion and cytotoxicity of natural killer cellsNKARTA INC·Filed 2020·Application pending·0 cites
- 1852US2024335536A1Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapyNKARTA INC·Filed 2021·Application pending·0 cites
- 1950US2023265390A1Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereofNKARTA INC·Filed 2021·Application pending·0 cites
- 2049US2023028399A1Bcma-directed cellular immunotherapy compositions and methodsNKARTA INC·Filed 2021·Application pending·0 cites
- 2146US2022233593A1Combinations of engineered natural killer cells and engineered t cells for immunotherapyNKARTA INC·Filed 2020·Application pending·0 cites
- 2240US12590148B2Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapyNKARTA INC·Filed 2019·Granted Mar 31, 2026·0 cites·22 claims
Join the waitlist — get patent alerts
Get an alert when NKARTA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →